Amy Tiersten, MD Email Amy Tiersten
-
- Position
- PROFESSOR | Medicine, Hematology and Medical Oncology
-
- Specialty
- Hematology-Oncology
-
- Language
- English
-
- Hospital Affiliation
- The Mount Sinai Hospital
-
- Phone
- Dubin Breast Center 212-241-3300212-241-3300
Dr. Tiersten sees patients in the Dubin Breast Center. She works collaboratively with Mount Sinai breast surgeons, radiation oncologists, radiologists, and other related subspecialists to provide care to breast cancer patients and conduct breast cancer research. Dr. Tiersten has extensive experience participating clinical trials, as well as being the Principal Investigator for national studies.
Clinical Focus
- Breast Cancer
- Gynecologic Cancers
- Medical Oncology
Research Topics
Anti-Tumor Therapy
Education
MD, New York University
BA, Barnard College/Columbia University
Residency, Internal Medicine
Mount Sinai Hospital
Fellowship, Hematology & Onc.
Memorial Sloan-Kettering
Language
English
2005
New award
New York University School of Medicine, Division of Oncology
Faculty of the Year Award
2000
New award
Columbia University College of Physicians & Surgeons
Teacher Recognition Award
1996
New award
American Society of Clinical Oncology
Merit Award
Tiersten AD, Grin CM, Kopf AW, Gottlieb GJ, Bart RS, Rigel DS, Friedman RJ, Levenstein MJ. Prospective follow-up for malignant melanoma in patients with atypical-mole (dysplastic-nevus) syndrome. The Journal of dermatologic surgery and oncology 1991 Jan; 17(1).
Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao TJ, Lepore J, Gilewski T, Currie V, Crown J. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995 Oct; 13(10).
Vahdat L, Raptis G, Fennelly D, Hamilton N, Reich L, Tiersten A, Harrison M, Hudis C, Moore M, Yao TJ. Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 1995 Nov; 1(11).
Tiersten A, Selleck M, Smith DH, Wertheim I, Kaufman E, Hershman D, Vahdat LT, Savage DG, MacArthur RB, Hesdorffer C. Phase I/II study of tandem cycles of high-dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society; 16(1).
Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, Frederick D, Bagiella E, Tiersten A, Nichols G, Garrett T, Savage D, Antman K, Hesdorffer CS, Balmaceda C. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clinical cancer research : an official journal of the American Association for Cancer Research 2001 May; 7(5).
Rothenberg ML, Liu PY, Wilczynski S, Hannigan EV, Weiner SA, Weiss GR, Hunter VJ, Chapman JA, Tiersten A, Kohler PC, Alberts DS. Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326). Gynecologic oncology 2001 Aug; 82(2).
Tiersten AD, Nelsen C, Talbot S, Vahdat L, Fine R, Troxel A, Brafman L, Shriberg L, Antman K, Petrylak DP. A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma. Cancer 2003 Feb; 97(3).
Vahdat LT, Balmaceda C, Papadopoulos K, Frederick D, Donovan D, Sharpe E, Kaufman E, Savage D, Tiersten A, Nichols G, Haythe J, Troxel A, Antman K, Hesdorffer CS. Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Bone marrow transplantation 2002 Aug; 30(3).
Hershman D, Weinberg M, Rosner Z, Alexis K, Tiersten A, Grann VR, Troxel A, Neugut AI. Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer. Journal of the National Cancer Institute 2003 Oct; 95(20).
Tiersten A, Wo J, Jacobson C, Weitzman A, Horwich T, Hesdorffer C, Savage D, Troxel A. Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer. Breast (Edinburgh, Scotland) 2004 Aug; 13(4).
Tiersten A, Ng YY, Pile-Spellman E, Nelsen C, Noguera-Irizarry W, Brafman R, Russo D, Troxel A, Johnson A. Relationship between mammographic breast density and tamoxifen in women with breast cancer. The breast journal; 10(4).
Tiersten AD, Selleck MJ, Hershman DL, Smith D, Resnik EE, Troxel AB, Brafman LB, Shriberg L. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecologic oncology 2004 Feb; 92(2).
Tiersten A, Selleck M, Smith DH, Wertheim I, Kaufman E, Hershman D, Vahdat LT, Savage DG, MacArthur RB, Hesdorffer C. Phase I/II study of tandem cycles of high-dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society; 16(1).
Vahdat LT, Cohen DJ, Zipin D, Lo KS, Donovan D, Savage D, Tiersten A, Nichols G, Troxel A, Hesdorffer CS. Randomized trial of low-dose interleukin-2 vs cyclosporine A and interferon-gamma after high-dose chemotherapy with peripheral blood progenitor support in women with high-risk primary breast cancer. Bone marrow transplantation 2007 Aug; 40(3).
Smith HO, Moon J, Wilczynski SP, Tiersten AD, Hannigan EV, Robinson WR, Rivkin SE, Anderson GL, Liu PY, Markman M. Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer. Gynecologic oncology 2009 Aug; 114(2).
Tiersten AD, Moon J, Smith HO, Wilczynski SP, Robinson WR, Markman M, Alberts DS. Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: a Southwest Oncology Group Study. Oncology 2009; 77(6).
Fasano J, Hershman D, Novik Y, Levinson B, Blozie K, Tiersten AD. Phase II Evaluation of Liposomal Doxorubicin with Docetaxel in Patients with Metastatic Breast Cancer. Breast care (Basel, Switzerland) 2010 Mar; 5(1).
Safra T, Andreopoulou E, Levinson B, Borgato L, Pothuri B, Blank S, Tiersten A, Boyd L, Curtin J, Muggia F. Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancer. Anticancer research 2010 Sep; 30(9).
Adams S, Kozhaya L, Martiniuk F, Meng TC, Chiriboga L, Liebes L, Hochman T, Shuman N, Axelrod D, Speyer J, Novik Y, Tiersten A, Goldberg JD, Formenti SC, Bhardwaj N, Unutmaz D, Demaria S. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Dec; 18(24).
Stein SM, Tiersten A, Hochster HS, Blank SV, Pothuri B, Curtin J, Shapira I, Levinson B, Ivy P, Joseph B, Guddati AK, Muggia F. A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2013 Nov; 23(9).
Warner E, Liebes L, Levinson B, Downey A, Tiersten A, Muggia F. Continuous-infusion topotecan and erlotinib: a study in topotecan-pretreated ovarian cancer assessing shed collagen epitopes as a marker of invasiveness. The oncologist 2014 Mar; 19(3).
Singh J, Novik Y, Stein S, Volm M, Meyers M, Smith J, Omene C, Speyer J, Schneider R, Jhaveri K, Formenti S, Kyriakou V, Joseph B, Goldberg JD, Li X, Adams S, Tiersten A. Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast cancer research : BCR 2014; 16(2).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Tiersten during 2017 and/or 2018. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose
- Amgen Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.